Climate entity
All 1 tracked stories fall under one category: regulation. Nektar Therapeutics is most often covered alongside Enphase Energy, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.9 in the same window.
Last mentioned: Mar 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Nektar Therapeutics is most often covered alongside Enphase Energy, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.9 in the same window. Source depth averages 3 original sources per story, versus 2.6 across the same-window beat baseline. We currently track 1 Climate story that mention Nektar Therapeutics, all published on March 22, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Climate stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nektar Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Lead Plaintiff Deadline
Final date for investors to petition the court to lead the Enphase class action.
Litigation Expansion
Pomerantz confirms additional filings and alerts for Enphase and Nektar Therapeutics.
Insider Sale
Director Thurman Rodgers sells 137,250 shares of Enphase stock.
Initial Filing
Pomerantz LLP commences class action proceedings against Enphase Energy.
Pomerantz LLP has filed a class action lawsuit against solar technology leader Enphase Energy, alleging securities law violations following a period of significant stock volatility. The litigation marks a critical regulatory challenge for the renewable energy sector as it navigates a broader market downturn.
Nektar Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
